Related Experiment Video
Updated: May 22, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pulmonary Infections in Adults: Community-Acquired Pneumonia
Thomas M File1, Julio A Ramirez2
1Infectious Disease Division - Summa Health, Akron, OH.
Abstract:
Community-acquired pneumonia (CAP) is a common and potentially serious illness, particularly in older patients and those with significant comorbidities. Recent evidence indicates diverse communities of microbes reside within the alveoli as part of the lung microbiome and may play a role in the development of pneumonia. A CAP diagnosis is based on the demonstration of a new infiltrate on imaging in a patient with symptoms and signs of pneumonia. Although vaccination has decreased its incidence, Streptococcus pneumoniae (pneumococcus) remains the most common bacterial cause of CAP. Macrolide resistance to S pneumoniae has increased in the United States. With their increasing availability, newer molecular testing methods (eg, respiratory pathogen polymerase chain reaction panel) play a significant role in the evaluation of respiratory viruses. Antimicrobial therapy for hospitalized patients should be based on the results of diagnostic studies to allow pathogen-directed therapy and optimal antimicrobial stewardship. The recommended duration for antimicrobial therapy is 3 to 5 days if there is good clinical improvement by day 2 or 3. Procalcitonin levels can be useful as an adjunct to clinical judgment for determining the appropriate duration of therapy. Smoking cessation and vaccination should be prioritized because they significantly reduce the incidence and severity of CAP.
Insights
Community-acquired pneumonia (CAP) is a common illness often caused by Streptococcus pneumoniae. Early diagnosis, pathogen-directed antimicrobial therapy, and preventive measures like vaccination are key to managing CAP effectively.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Microbiology
Background:
- Community-acquired pneumonia (CAP) is a significant global health concern, particularly impacting vulnerable populations like the elderly and those with comorbidities.
- The lung microbiome's role in CAP pathogenesis is an emerging area of research.
- Streptococcus pneumoniae (pneumococcus) persists as the leading bacterial cause of CAP, despite vaccination efforts, with increasing macrolide resistance noted in the US.
Purpose of the Study:
- To provide an overview of current understanding and management strategies for community-acquired pneumonia.
- To highlight the diagnostic role of newer molecular testing methods.
- To emphasize the importance of antimicrobial stewardship and preventive measures.
Main Methods:
- Review of current literature and clinical guidelines for CAP diagnosis and treatment.
- Discussion of diagnostic modalities including imaging, microbiological testing, and newer molecular assays (e.g., respiratory pathogen polymerase chain reaction panels).
- Evaluation of antimicrobial therapy principles, duration, and the adjunctive role of biomarkers like procalcitonin.
Main Results:
- CAP diagnosis relies on clinical signs, symptoms, and new imaging infiltrates.
- Molecular testing aids in identifying viral pathogens, complementing traditional diagnostics.
- Pathogen-directed antimicrobial therapy, guided by diagnostic studies, is crucial for optimal outcomes and stewardship.
- A 3-5 day course of antibiotics is recommended with clinical improvement.
Conclusions:
- Effective CAP management integrates timely diagnosis, pathogen-specific antimicrobial therapy, and judicious use of diagnostic tools.
- Antimicrobial stewardship principles, including appropriate therapy duration guided by clinical response and biomarkers, are essential.
- Preventive strategies, including smoking cessation and vaccination, are paramount in reducing CAP incidence and severity.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
15:43Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: